11/8
10:34 am
ewtx
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) had its price target raised by analysts at Wedbush from $44.00 to $45.00. They now have an "outperform" rating on the stock.
Low
Report
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) had its price target raised by analysts at Wedbush from $44.00 to $45.00. They now have an "outperform" rating on the stock.
11/7
08:00 am
ewtx
Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Medium
Report
Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
10/11
08:41 am
ewtx
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) had its price target raised by analysts at Piper Sandler from $48.00 to $51.00. They now have an "overweight" rating on the stock.
Medium
Report
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) had its price target raised by analysts at Piper Sandler from $48.00 to $51.00. They now have an "overweight" rating on the stock.
10/1
08:00 am
ewtx
Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society
Medium
Report
Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society
9/20
05:28 am
ewtx
Edgewise's EDG-7500 shows benefit in two obstructive HCM trials [Yahoo! Finance]
Medium
Report
Edgewise's EDG-7500 shows benefit in two obstructive HCM trials [Yahoo! Finance]
9/19
02:03 pm
ewtx
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) had its price target raised by analysts at Truist Financial Co. from $25.00 to $33.00. They now have a "buy" rating on the stock.
Low
Report
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) had its price target raised by analysts at Truist Financial Co. from $25.00 to $33.00. They now have a "buy" rating on the stock.
9/19
01:15 pm
ewtx
Why Edgewise Therapeutics Stock Is Up 50% on Thursday [Yahoo! Finance]
Medium
Report
Why Edgewise Therapeutics Stock Is Up 50% on Thursday [Yahoo! Finance]
9/19
07:00 am
ewtx
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)
High
Report
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)
9/17
04:11 pm
ewtx
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time [Yaho
Medium
Report
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time [Yaho
9/17
04:01 pm
ewtx
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time
Medium
Report
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time
9/17
03:10 pm
ewtx
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $32.00 price target on the stock.
Low
Report
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $32.00 price target on the stock.
9/3
04:59 pm
ewtx
Dyne stock tumbles 31% amid drug updates, management changes [Seeking Alpha]
Medium
Report
Dyne stock tumbles 31% amid drug updates, management changes [Seeking Alpha]